Pancreatic Cancer’s ‘Sugar-Coated’ Defense Mechanism unveiled, New Antibody Shows Promise
Table of Contents
A groundbreaking revelation from Northwestern Medicine reveals how pancreatic tumors evade the immune system using a unique sugar-based disguise, paving the way for a novel antibody therapy that could considerably improve treatment outcomes for this notoriously difficult cancer.
Pancreatic cancer remains one of the most challenging cancers to treat, wiht a dismal five-year survival rate of just 13%. The disease often resists even the most advanced immunotherapies, prompting scientists to seek a deeper understanding of it’s immune-evading tactics.
For years, researchers have known that the immune response within pancreatic tumors is unusually suppressed. A team at Northwestern University Feinberg School of Medicine set out to determine why, and what mechanisms the cancer cells employ to avoid detection. Their investigation led to the identification of a specific sugar coating on the surface of pancreatic cancer cells, linked to a surface protein called integrin α3β1.
This sugar coating allows the protein to bind to a sensor on immune cells called Siglec-10, sending a false “stand down” signal. As one researcher explained, “In short, the tumor sugar-coats itself – a classic wolf-in-sheep’s-clothing move – to escape immune surveillance.” This clever disguise effectively renders the tumor invisible to the immune system, allowing it to grow unchecked.
reawakening the Immune System with a novel Antibody
Once the mechanism of immune evasion was identified, the Northwestern scientists developed monoclonal antibodies designed to block the interaction between integrin α3β1 and Siglec-10. In laboratory tests and two animal models, these antibodies successfully disrupted the “stand down” signal, reawakening immune cells and enabling them to target and destroy cancer cells. Tumors in treated mice exhibited significantly slower growth compared to those in untreated controls.
Developing these antibodies was a complex undertaking. “When you make an antibody, you test what are called hybridomas, cells that produce antibodies. We screened thousands before finding the one that worked,” a senior researcher noted.The success represents a major breakthrough after six years of dedicated research.
Looking Ahead: Combination Therapies and Clinical Trials
The next phase of research will focus on combining the newly developed antibody with existing chemotherapy and immunotherapy treatments.Researchers believe this combination approach holds the greatest potential for achieving complete remission.”There’s a strong scientific rationale to believe combination therapy will allow us to reach our ultimate goal: a full remission,” a lead scientist stated. “We don’t wont onyl a 40% tumor reduction or slowing down. We want to remove the cancer altogether.”
The team is currently refining the antibody for human use and preparing for early safety and dosing studies. Together, they are developing a companion diagnostic test to identify patients whose tumors are most likely to respond to this sugar-targeting therapy, ensuring the right treatment reaches the right individuals.
While it is estimated that it may take approximately five years before this therapy becomes available to patients, the potential impact is substantial. Beyond pancreatic cancer, researchers are investigating weather this same “sugar-coat” trick is employed by other difficult-to-treat cancers, such as glioblastoma, and even in non-cancerous diseases where the immune system is compromised.
The research is rooted in the growing field of glyco-immunology, which explores the intricate relationship between sugars and the immune system.”We’re just scratching the surface of this field,” a researcher explained.”Here at Northwestern,we’re positioned to turn these sugar-based insights into real treatments for cancer,infectious diseases and aging-related conditions.”
The study’s senior author is affiliated with the Robert H. Lurie Thorough Cancer Center of Northwestern University.
Source: Saini, P., et al.(2025). Targeting Interactions Between Siglec-10 and α3β1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer. Cancer Research. doi.org/10.1158/0008-5472.can-25-0977.
